Photo of David M. Lewinsohn, M.D., Ph.D.

David M. Lewinsohn M.D., Ph.D.

    • Professor of Medicine, Division of Pulmonary and Critical Care Medicine School of Medicine
    • Molecular Microbiology and Immunology Graduate Program School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine

After receiving his B.S. in biology from Haverford College, David Lewinsohn attended Stanford University School of Medicine. In 1989 he received his Ph.D. in cancer biology and received his M.D. the same year. Dr. Lewinsohn was a Fellow of Pulmonary and Critical Care Medicine at the University of Washington, Seattle, WA, from 1993-1996, and a senior fellow and acting instructor from 1996-1998. During 1996-1998 he was also an investigator at the Infectious Disease Research Institute in Seattle, WA.

Education

  • M.D., Ph.D., Stanford University, Palo Alto California 1989
  • Residency:

    • Categorical Internal Medicine Residency, University of California, San Francisco 1992
  • Fellowship:

    • Categorical Internal Medicine Internship, University of California San Francisco 1990Pulmonary and Critical Care Medicine, University of Washington 1996
  • Certifications:

    • Pulmonary 1996Critical Care Medicine 1997

Publications

  • "Characterization of specific CD4 and CD8 T-cell responses in QuantiFERON TB Gold-Plus TB1 and TB2 tubes." Tuberculosis  In: , Vol. 113, 01.12.2018, p. 239-241.
  • "MR1-dependent antigen presentation." Seminars in Cell and Developmental Biology  In: , Vol. 84, 01.12.2018, p. 58-64.
  • "Incipient and subclinical tuberculosis : A clinical review of early stages and progression of infection." Clinical Microbiology Reviews  In: , Vol. 31, No. 4, e00021-18, 01.10.2018.
  • "Role of MAIT cells in pulmonary bacterial infection." Molecular Immunology  In: , Vol. 101, 01.09.2018, p. 155-159.
  • "Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis." Tuberculosis  In: , Vol. 112, 01.09.2018, p. 52-61.
  • "MR1 displays the microbial metabolome driving selective MR1-restricted T cell receptor usage." Science immunology  In: , Vol. 3, No. 25, 13.07.2018.
  • "Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine." Infection and Immunity  In: , Vol. 86, No. 7, e00014-18, 01.07.2018.
  • "Riboflavin metabolism variation among clinical isolates of streptococcus pneumoniae results in differential activation of mucosal-Associated invariant T cells." American Journal of Respiratory Cell and Molecular Biology  In: , Vol. 58, No. 6, 01.06.2018, p. 767-776.
  • "Interplay of strain and race/ethnicity in the innate immune response to M. tuberculosis." PLoS One  In: , Vol. 13, No. 5, e0195392, 01.05.2018.
  • "MAIT cells and microbial immunity." Immunology and Cell Biology  In: , 01.01.2018.
  • "Early clearance versus control : What is the meaning of a negative tuberculin skin test or interferon-gamma release assay following exposure to Mycobacterium tuberculosis? [version 1; referees: 2 approved]." F1000Research  In: , Vol. 7, 664, 01.01.2018.
  • "Diagnostic Challenge of Tuberculosis Heterogeneity." Seminars in Respiratory and Critical Care Medicine  In: , Vol. 39, No. 3, 01.01.2018, p. 286-296.
  • "HLA-E Presents Glycopeptides from the Mycobacterium tuberculosis Protein MPT32 to Human CD8 T cells." Scientific Reports  In: , Vol. 7, No. 1, 4622, 01.12.2017.
  • "Comprehensive definition of human immunodominant CD8 antigens in tuberculosis." npj Vaccines  In: , Vol. 2, No. 1, 8, 01.12.2017.
  • "T cell recognition of Mycobacterium tuberculosis peptides presented by HLA-E derived from infected human cells." PLoS One  In: , Vol. 12, No. 11, e0188288, 01.11.2017.
  • "Biomarkers of Tuberculosis Severity and Treatment Effect : A Directed Screen of 70 Host Markers in a Randomized Clinical Trial." EBioMedicine  In: , Vol. 25, 01.11.2017, p. 112-121.
  • "IL-17 production from T helper 17, mucosal-associated invariant T, and γδ cells in tuberculosis infection and disease." Frontiers in Immunology  In: , Vol. 8, No. OCT, 1252, 11.10.2017.
  • "Polyfunctional CD4 T cells as targets for tuberculosis vaccination." Frontiers in Immunology  In: , Vol. 8, No. OCT, 1262, 05.10.2017.
  • "An expanding role for environmental microbes in shaping the immune response to infection with mycobacterium tuberculosis." American Journal of Respiratory and Critical Care Medicine  In: , Vol. 196, No. 6, 15.09.2017, p. 677-679.
  • "The Mycobacterium tuberculosis MmpL11 cell wall lipid transporter is important for biofilm formation, intracellular growth, and nonreplicating persistence." Infection and Immunity  In: , Vol. 85, No. 8, 00131-17, 01.08.2017.
  • "MR1-restricted mucosal-associated invariant T (MAIT) cells respond to mycobacterial vaccination and infection in nonhuman primates." Mucosal Immunology  In: , Vol. 10, No. 3, 01.05.2017, p. 802-813.
  • "Diagnosis of tuberculosis in adults and children." Annals of the American Thoracic Society  In: , Vol. 14, No. 2, 01.02.2017, p. 275-278.
  • "Tuberculosis Infectiousness and Host Susceptibility." Journal of Infectious Diseases  In: , Vol. 216, 01.01.2017, p. S636-S643.
  • "Official American thoracic society/Infectious diseases society of America/Centers for disease control and prevention clinical practice guidelines : diagnosis of tuberculosis in adults and children." Clinical Infectious Diseases  In: , Vol. 64, No. 2, 2017, p. 111-115.
  • "Official American thoracic society/Infectious diseases society of America/Centers for disease control and prevention clinical practice guidelines : Diagnosis of tuberculosis in adults and children[1]." Clinical Infectious Diseases  In: , Vol. 64, No. 2, 2017, p. e1-e33.
  • "A polymorphism in human MR1 is associated with mRNA expression and susceptibility to tuberculosis." Genes and Immunity  In: , 24.11.2016.
  • "Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target : Lessons from a Phase I Trial of the AERAS-402 Vaccine." Scientific Reports  In: , Vol. 6, 36355, 02.11.2016.
  • "Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigens." Nature Communications  In: , Vol. 7, 12506, 16.08.2016.
  • "Engineering of isogenic cells deficient for MR1 with a CRISPR/Cas9 lentiviral system : Tools to study microbial antigen processing and presentation to human mr1-restricted t cells." Journal of Immunology  In: , Vol. 197, No. 3, 01.08.2016, p. 971-982.
  • "Endosomal MR1 Trafficking Plays a Key Role in Presentation of Mycobacterium tuberculosis Ligands to MAIT Cells." PLoS Pathogens  In: , Vol. 12, No. 3, e1005524, 01.03.2016.

Additional information

Edit profile